F-10POS: Oncolytics Biotech Deregisters Unsold Securities
Deregistration of Securities
Oncolytics Biotech Inc. has filed a post-effective amendment to deregister unsold securities from multiple previous registration statements.
Summary
- Oncolytics Biotech Inc. is filing a post-effective amendment to remove unsold securities from ten previous registration statements filed between 2007 and 2024.
- These registration statements covered various offerings including units, common shares, subscription receipts, warrants, and debt securities.
- The amendment specifically pertains to the deregistration of the unsold portions of securities that were registered under these statements.
- The filing is made pursuant to Rule 467(b) and is proposed to become effective on April 16, 2026, at 4:30 p.m. Eastern time.
Sentiment
Score: 3
Explanation: StockSavvy.ai views this filing as having a neutral to slightly negative sentiment, as it primarily concerns the deregistration of unsold securities, implying that previous offering efforts did not fully materialize as planned.
Future Outlook
The filing indicates that the proposed effective date for this amendment is April 16, 2026, at 4:30 p.m. Eastern time, at which point the deregistration of unsold securities will take effect.
Industry Context
StockSavvy.ai notes that this filing is a procedural administrative action by Oncolytics Biotech to clean up its historical SEC filings by removing registration statements for securities that were never issued or sold. This is a common practice for companies that have completed offerings or have had registration statements expire without full utilization.
Stakeholder Impact
- Shareholders: This filing does not directly impact current shareholders as it pertains to securities that were not sold. It may indirectly signal past offering challenges.
Next Steps
- The post-effective amendment is scheduled to become effective on April 16, 2026, at 4:30 p.m. Eastern time.
- Upon effectiveness, the unsold portions of securities registered under the listed registration statements will be removed from registration.
Key Dates
| Date | Description |
|---|---|
| February 5, 2007 | Initial filing date for Registration Statement No. 333-140460. |
| February 8, 2007 | Initial filing date for Registration Statement No. 333-140529. |
| June 6, 2008 | Initial filing date for Registration Statement No. 333-151513. |
| June 2, 2010 | Initial filing date for Registration Statement No. 333-167250. |
| June 21, 2012 | Initial filing date for Registration Statement No. 333-182260. |
| July 25, 2014 | Initial filing date for Registration Statement No. 333-197633. |
| April 25, 2018 | Initial filing date for Registration Statement No. 333-224432. |
| June 8, 2020 | Initial filing date for Registration Statement No. 333-239025. |
| June 10, 2022 | Initial filing date for Registration Statement No. 333-265510. |
| July 25, 2024 | Initial filing date for Registration Statement No. 333-281009. |
| April 8, 2026 | Date of filing of the post-effective amendment and signing of the document. |
| April 16, 2026 | Proposed effective date of the post-effective amendment. |
Keywords
Oncolytics Biotech, SEC Filing, Registration Statement, Deregistration, Securities, Form F-10, Post-Effective Amendment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.